Needham analyst Joseph Stringer reiterated a Buy rating on Cidara Therapeutics (CDTX – Research Report) today and set a price target of $6.00. The company's shares closed last Wednesday at $0.59, close to its 52-week low of $0.57. According to TipRanks.com, Stringer is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -29.3% and a 18.9% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Apellis Pharmaceuticals, and Phathom Pharmaceuticals. Cidara Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $5.00, which is a 618.4% upside from current levels.
https://www.tipranks.com/news/blurbs/needham-thinks-cidara-therapeutics-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral